BIO on the American Road Tours Gene Therapy Hub in Ohio

Why It Matters

Ohio now offers a complete life‑science value chain, attracting biotech capital and speeding U.S. clinical trials to keep pace with China’s growing influence.

Key Takeaways

• Nationwide Children’s created two of eight FDA‑approved gene therapies.
• OSU’s gene therapy institute targets rare neuro‑genetic disorders.
• Sarepta’s 140k‑sq‑ft center boosts Ohio manufacturing capacity.
• Ohio life‑science value chain includes $900M Amgen expansion.
• $300M Jobs Ohio funding fuels innovation districts and talent pipelines.

Pulse Analysis

Ohio’s biotech sector has evolved from a regional talent pool into a nationally recognized gene‑therapy powerhouse. With 65,000 jobs and breakthroughs that include two of the FDA’s first eight approved gene therapies, the state showcases how public‑private partnerships—exemplified by Nationwide Children’s Hospital’s technology‑transfer model—can translate laboratory discoveries into marketable treatments. This collaborative "Columbus way" leverages major universities, research hospitals, and venture capital to create a dense innovation cluster that draws top scientists and accelerates product commercialization.

A critical advantage for Ohio lies in its focus on streamlining clinical trials, an area where the U.S. has lagged behind China. Nationwide Children’s has built dedicated resources to fast‑track first‑in‑human studies, while Ohio State University’s Big Ten Neurosurgery Consortium aims to centralize IRB reviews and contracting, cutting start‑up times for multi‑site trials. These initiatives not only reduce bottlenecks but also position Ohio as a preferred site for sponsors seeking rapid patient access, thereby strengthening the nation’s competitive edge in therapeutic development.

Economic momentum reinforces the scientific gains. Amgen’s planned $900 million expansion in New Albany adds significant manufacturing capacity, and Jobs Ohio’s $300 million infusion supports innovation districts across Cleveland, Cincinnati and Columbus. Combined with the presence of logistics leaders like DHL Life Sciences and Cardinal Health, Ohio offers end‑to‑end infrastructure—from discovery to distribution. This comprehensive ecosystem is attracting new investments, retaining homegrown IP, and ensuring a pipeline of skilled talent, all of which signal sustained growth for the state’s biotech industry.